News

BC007 Eliminates Autoantibodies Linked to Disease in 80% of Patients
First Drug to Attack the Cause of Dilated Cardiomyopathy
ZUG, Switzerland, and BERLIN, Feb. 26, 2018 – The first drug designed to eliminate autoantibodies that are a major cause of heart failure and to treat heart failure symptoms was effective and well-tolerated in a Phase 1 clinical study, according to an oral presentatio...

Berlin Cures Holding AG announces start of phase-1 study of BC007
ZURICH (Switzerland), November 14, 2016 -- Berlin Cures Holding AG announces the start of the clinical Phase-1-first-in-human-study of its drug candidate BC007. The study is a 2-part design with part 1 being a randomized, double-blinded, ascending single-dose study in healthy subjects, followed by part 2, which is an open, ascen...